Future of diagnostics : personal genetics services due for explosive growth
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Valor |
|---|---|---|---|
| LDR | 00000cam a22000004b 4500 | ||
| 001 | MAP20170035831 | ||
| 003 | MAP | ||
| 005 | 20171107133719.0 | ||
| 008 | 171107s201710 usa|||| ||| ||eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 041 | 0 | $aeng | |
| 084 | $a931 | ||
| 100 | 1 | $0MAPA20170014812$aWylie, Craig | |
| 245 | 0 | 0 | $aFuture of diagnostics$b: personal genetics services due for explosive growth$cCraig Wylie |
| 260 | $aMadrid$bArthur D. Little$ccop. 2017 | ||
| 300 | $a12 p. | ||
| 520 | $aAccess to genetic information is becoming critical to the effectiveness of a new wave of medical treatments that are becoming available now. Personalized genetic services companies will act as a disruptive forces that are consumerizing genomic testing and driving rapid transformation of an industry that we expect to become a major force in personalized medicine. In this report, we consider how large this industry is likely to get in the next 10 years and start to evaluate how pharmaceutical companies, payers, providers and medtech companies will be impacted by the shift. We believe the emergence of ever cheaper testing technology means manufacturers can enhance clinical trials, payers can be selective in authorizing treatment payouts, and patients can have more confidence in outcomes | ||
| 650 | 4 | $0MAPA20080591885$aMedicina preventiva | |
| 650 | 4 | $0MAPA20080547424$aGenética | |
| 650 | 4 | $0MAPA20080557850$aDiagnóstico | |
| 650 | 4 | $0MAPA20080586546$aNuevas tecnologías | |
| 650 | 4 | $0MAPA20080591526$aInformación privada | |
| 650 | 4 | $0MAPA20080588533$aTratamiento médico | |
| 710 | 2 | $0MAPA20080440602$aArthur D. Little |